Cradle Bio vs Beam Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cradle provides an AI platform for protein engineering that accelerates the design of improved enzymes, antibodies, and other biologics for industrial and therapeutic use.
About
Cradle Bio is an AI protein engineering company founded in 2021 in Amsterdam, having raised $73M to build an AI-powered protein design platform. The platform combines generative AI with wet-lab experimentation to accelerate the iterative process of engineering proteins with improved stability, activity, and manufacturability. Cradle's technology enables researchers to design thousands of protein variants computationally and prioritize those most likely to succeed in laboratory validation, compressing protein engineering timelines from years to months. The company serves both industrial biotechnology customers engineering enzymes for biomanufacturing and pharmaceutical companies developing next-generation antibody therapeutics. Cradle partners with contract research organizations and biopharmaceutical companies to integrate AI-assisted protein design into existing discovery workflows. The company has been recognized as a leader in the European deep tech ecosystem and positions protein engineering AI as enabling a new era of designed biologics for medicine and sustainable manufacturing.
Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.
About
Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.